PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
about
Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice.History and future technical innovation in positron emission tomography.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Current status of theranostics in prostate cancer.Radiotheranostics in Cancer Diagnosis and Management.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.Effect of Carbohydration on the Theranostic Tracer PSMA I&TSynthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
P2860
Q33601455-DBBF4E6F-1A15-4912-845A-A80CEB177BF4Q38731565-B1C9519D-D53B-456F-869F-C874245E94CEQ38821290-2744DECC-7BBE-4809-B2E2-6AAA97CF8AD9Q41475179-7B7A892A-0E8D-4A77-A038-AE12EEFF8B18Q41856358-1D1C32D4-7414-4643-B87F-056C6B1F2BDDQ47158291-C2E76582-BD10-4A52-9CC5-6755D91787FCQ47241139-ED2AA2AD-0BD6-4E53-BBD1-F070BC9481C1Q47719762-FDC44867-6F1B-462B-81AE-999E9FF44482Q48107095-3F78CA1A-2ED5-4A33-9BAD-EC7013A47612Q48194472-4B47C033-F450-464C-93AA-0E40791B9C19Q53695831-C55D43F0-A4DA-4686-AE15-0AA21FBFCC69Q54923034-03D074FC-98AE-467F-AD94-6E42143949B9Q55415632-7117FA15-5E08-4223-81C6-DEC02FA1A7A4Q57173866-A5018A56-CEF0-4FF4-8814-1890053A3D9EQ58723804-1A50F3D6-5840-48C6-9A76-6F11F66CEFED
P2860
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
PSMA-Based Radioligand Therapy ...... d Berka Experience Since 2013.
@en
type
label
PSMA-Based Radioligand Therapy ...... d Berka Experience Since 2013.
@en
prefLabel
PSMA-Based Radioligand Therapy ...... d Berka Experience Since 2013.
@en
P2093
P1476
PSMA-Based Radioligand Therapy ...... d Berka Experience Since 2013.
@en
P2093
Aviral Singh
Christiane Schuchardt
Hans-Juergen Wester
Harshad R Kulkarni
Karin Niepsch
Manal Sayeg
Richard P Baum
Yevgeniy Leshch
P304
P356
10.2967/JNUMED.115.170167
P407
P433
P577
2016-10-01T00:00:00Z